Mast Cells
Cell Degranulation
Histamine Release
Tryptases
Chymases
Receptors, IgE
p-Methoxy-N-methylphenethylamine
Immunoglobulin E
Mastocytosis
Cromolyn Sodium
Proto-Oncogene Proteins c-kit
Histamine
Anaphylaxis
Mastocytosis, Systemic
Serine Endopeptidases
Stem Cell Factor
Peritoneal Cavity
Passive Cutaneous Anaphylaxis
Leukemia, Mast-Cell
beta-N-Acetylhexosaminidases
Basophils
Carboxypeptidases A
Ketotifen
Cell Count
Cells, Cultured
Thioxanthenes
Skin
Mast-Cell Sarcoma
Tolonium Chloride
Hypersensitivity
Urticaria Pigmentosa
Anti-Allergic Agents
Connective Tissue Cells
Leukemia, Basophilic, Acute
Prostaglandin D2
Interleukin-3
Bone Marrow Cells
Leukotriene C4
Mice, Knockout
Cytokines
Histamine H1 Antagonists
Trichinellosis
Leukotrienes
Nippostrongylus
Microphthalmia-Associated Transcription Factor
Exocytosis
Interleukin-4
Signal Transduction
Eosinophils
Lung
Interleukin-9
Histidine Decarboxylase
Trichinella spiralis
Alcian Blue
RNA, Messenger
Calcium
Inflammation
Hematopoietic Cell Growth Factors
Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. (1/5252)
We have identified Socs1 as a downstream component of the Kit receptor tyrosine kinase signalling pathway. We show that the expression of Socs1 mRNA is rapidly increased in primary bone marrow-derived mast cells following exposure to Steel factor, and Socs1 inducibly binds to the Kit receptor tyrosine kinase via its Src homology 2 (SH2) domain. Previous studies have shown that Socs1 suppresses cytokine-mediated differentiation in M1 cells inhibiting Janus family kinases. In contrast, constitutive expression of Socs1 suppresses the mitogenic potential of Kit while maintaining Steel factor-dependent cell survival signals. Unlike Janus kinases, Socs1 does not inhibit the catalytic activity of the Kit tyrosine kinase. In order to define the mechanism by which Socs1-mediated suppression of Kit-dependent mitogenesis occurs, we demonstrate that Socs1 binds to the signalling proteins Grb-2 and the Rho-family guanine nucleotide exchange factors Vav. We show that Grb2 binds Socs1 via its SH3 domains to putative diproline determinants located in the N-terminus of Socs1, and Socs1 binds to the N-terminal regulatory region of Vav. These data suggest that Socs1 is an inducible switch which modulates proliferative signals in favour of cell survival signals and functions as an adaptor protein in receptor tyrosine kinase signalling pathways. (+info)Borrelia burgdorferi spirochetes induce mast cell activation and cytokine release. (2/5252)
The Lyme disease spirochete, Borrelia burgdorferi, is introduced into human hosts via tick bites. Among the cell types present in the skin which may initially contact spirochetes are mast cells. Since spirochetes are known to activate a variety of cell types in vitro, we tested whether B. burgdorferi spirochetes could activate mast cells. We report here that freshly isolated rat peritoneal mast cells or mouse MC/9 mast cells cultured in vitro with live or freeze-thawed B. burgdorferi spirochetes undergo low but detectable degranulation, as measured by [5-3H] hydroxytryptamine release, and they synthesize and secrete the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha). In contrast to findings in previous studies, where B. burgdorferi-associated activity was shown to be dependent upon protein lipidation, mast cell TNF-alpha release was not induced by either lipidated or unlipidated recombinant OspA. This activity was additionally shown to be protease sensitive and surface expressed. Finally, comparisons of TNF-alpha-inducing activity in known low-, intermediate-, and high-passage B. burgdorferi B31 isolates demonstrated passage-dependent loss of activity, indicating that the activity is probably plasmid encoded. These findings document the presence in low-passage B. burgdorferi spirochetes of a novel lipidation-independent activity capable of inducing cytokine release from host cells. (+info)gp49B1 inhibits IgE-initiated mast cell activation through both immunoreceptor tyrosine-based inhibitory motifs, recruitment of src homology 2 domain-containing phosphatase-1, and suppression of early and late calcium mobilization. (3/5252)
We define by molecular, pharmacologic, and physiologic approaches the proximal mechanism by which the immunoglobulin superfamily member gp49B1 inhibits mast cell activation mediated by the high affinity Fc receptor for IgE (FcepsilonRI). In rat basophilic leukemia-2H3 cells expressing transfected mouse gp49B1, mutation of tyrosine to phenylalanine in either of the two immunoreceptor tyrosine-based inhibitory motifs of the gp49B1 cytoplasmic domain partially suppressed gp49B1-mediated inhibition of exocytosis, whereas mutation of both abolished inhibitory capacity. Sodium pervanadate elicited tyrosine phosphorylation of native gp49B1 and association of the tyrosine phosphatases src homology 2 domain-containing phosphatase-1 (SHP-1) and SHP-2 in mouse bone marrow-derived mast cells (mBMMCs). SHP-1 associated transiently with gp49B1 within 1 min after coligation of gp49B1 with cross-linked FcepsilonRI in mBMMCs. SHP-1-deficient mBMMCs exhibited a partial loss of gp49B1-mediated inhibition of FcepsilonRI-induced exocytosis at concentrations of IgE providing optimal exocytosis, revealing a central, but not exclusive, SHP-1 requirement in the counter-regulatory pathway. Coligation of gp49B1 with cross-linked FcepsilonRI on mBMMCs inhibited early release of calcium from intracellular stores and subsequent influx of extracellular calcium, consistent with SHP-1 participation. Because exocytosis is complete within 2 min in mBMMCs, our studies establish a role for SHP-1 in the initial counter-regulatory cellular responses whereby gp49B1 immunoreceptor tyrosine-based inhibition motifs rapidly transmit inhibition of FcepsilonRI-mediated exocytosis. (+info)Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. (4/5252)
Immunohistochemical, cytochemical and ultrastructural data showing vivid angiogenesis and numerous mast cells (MCs) in the bone marrow of 24 patients with active multiple myeloma (MM) compared with 34 patients with non-active MM and 22 patients with monoclonal gammopathy of undetermined significance (MGUS) led us to hypothesize that angiogenesis parallels progression of MM, and that MCs participate in its induction via angiogenic factors in their secretory granules. (+info)Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. (5/5252)
Urocortin (Ucn) is related to corticotropin-releasing hormone (CRH), and both are released in the brain under stress where they stimulate CRH 1 and 2 receptors (CRHR). Outside the brain, they may have proinflammatory actions through activation of mast cells, which are located perivascularly close to nerve endings and degranulate in response to acute psychological stress. Here, we report that a concentration of intradermal Ucn as low as 10 nM induced dose-dependent rat skin mast cell degranulation and increased vascular permeability. This effect appeared to be equipotent to that of calcitonin gene-related peptide and neurotensin. Ucn-induced skin vasodilation was inhibited by pretreatment with the mast cell stabilizer disodium cromoglycate (cromolyn) and was absent in the mast cell-deficient W/Wv mice. The selective nonpeptide CRH receptor 1 antagonist, antalarmin and the nonselective peptide antagonist astressin both reduced vascular permeability triggered by Ucn but not that by Substance P or histamine. In contrast, the peptide antagonist alpha-helical CRH-(9-41) reduced the effect of all three. The vasodilatory effect of Ucn was largely inhibited by pretreatment with H1 receptor antagonists, suggesting that histamine is the major mediator involved in vitro. Neuropeptide depletion of sensory neurons, treatment with the ganglionic blocker hexamethonium, or in situ skin infiltration with the local anesthetic lidocaine did not affect Ucn-induced vascular permeability, indicating that its in situ effect was not mediated through the peripheral nervous system. These results indicate that Ucn is one of the most potent triggers of rat mast cell degranulation and skin vascular permeability. This effect of Ucn may explain stress-induced disorders, such as atopic dermatitis or psoriasis, and may lead to new forms of treatment. (+info)Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. (6/5252)
1. The effect of IL-4 on responses to intraplantar (i.pl.) carrageenin, bradykinin, TNFalpha, IL-1beta, IL-8 and PGE2 was investigated in a model of mechanical hyperalgesia in rats. Also, the cellular source of the IL-4 was investigated. 2. IL-4, 30 min before the stimulus, inhibited responses to carrageenin, bradykinin, and TNFalpha, but not responses to IL-1beta, IL-8 and PGE2. 3. IL-4, 2 h before the injection of IL-1beta, did not affect the response to IL-1beta, whereas IL-4, 12 or 12+2 h before the IL-1beta, inhibited the hyperalgesia (-30%, -74%, respectively). 4. In murine peritoneal macrophages, murine IL-4 for 2 h before stimulation with LPS, inhibited (-40%) the production of IL-1beta but not PGE2. Murine IL-4 (for 16 h before stimulation with LPS) inhibited LPS-stimulated PGE2 but not IL-1beta. 5. Anti-murine IL-4 antibodies potentiated responses to carrageenin, bradykinin and TNFalpha, but not IL-1beta and IL-8, as well as responses to bradykinin in athymic rats but not in rats depleted of mast cells with compound 40/80. 6. These data suggest that IL-4 released by mast cells limits inflammatory hyperalgesia. During the early phase of the inflammatory response the mode of action of the IL-4 appears to be inhibition of the production TNFalpha, IL-1beta and IL-8. In the later phase of the response, in addition to inhibiting the production of pro-inflammatory cytokines, IL-4 also may inhibit the release of PGs. (+info)Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. (7/5252)
BACKGROUND: Activation of vascular chymase plays a major role in myointimal hypertrophy after vascular injury by augmenting the production of angiotensin (ANG) II. Because chymase is synthesized mainly in mast cells, we assumed that the chymase-dependent ANG II formation could be downregulated by tranilast, a mast cell-stabilizing antiallergic agent. We have assessed inhibitory effects of tranilast on neointima formation after balloon injury in the carotid artery of dogs, which share a similar ANG II-forming chymase with humans, and further explored the pathophysiological significance of vascular chymase. METHODS AND RESULTS: Either tranilast (50 mg/kg BID) or vehicle was orally administered to beagles for 2 weeks before and 4 weeks after balloon injury. Four weeks after the injury, remarkable neointima was formed in the carotid arteries of vehicle-treated dogs. Chymase mRNA levels and chymaselike activity of vehicle-treated injured arteries were increased 10.2- and 4.8-fold, respectively, those of uninjured arteries. Angiotensin-converting enzyme (ACE) activity was slightly increased in the injured arteries, whereas ACE mRNA levels were not. Tranilast treatment completely prevented the increase in chymaselike activity, reduced the chymase mRNA levels by 43%, and decreased the carotid intima/media ratio by 63%. In vehicle-treated injured arteries, mast cell count in the adventitia showed a great increase, which was completely prevented by the tranilast treatment. Vascular ACE activity and mRNA levels were unaffected by tranilast. CONCLUSIONS: Tranilast suppressed chymase gene expression, which was specifically activated in the injured arteries, and prevented neointima formation. Suppression of the chymase-dependent ANG II-forming pathway may contribute to the beneficial effects of tranilast. (+info)Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase. (8/5252)
Bruton's tyrosine kinase (Btk) plays pivotal roles in mast cell activation as well as in B cell development. Btk mutations lead to severe impairments in proinflammatory cytokine production induced by cross-linking of high-affinity IgE receptor on mast cells. By using an in vitro assay to measure the activity that blocks the interaction between protein kinase C and the pleckstrin homology domain of Btk, terreic acid (TA) was identified and characterized in this study. This quinone epoxide specifically inhibited the enzymatic activity of Btk in mast cells and cell-free assays. TA faithfully recapitulated the phenotypic defects of btk mutant mast cells in high-affinity IgE receptor-stimulated wild-type mast cells without affecting the enzymatic activities and expressions of many other signaling molecules, including those of protein kinase C. Therefore, this study confirmed the important roles of Btk in mast cell functions and showed the usefulness of TA in probing into the functions of Btk in mast cells and other immune cell systems. Another insight obtained from this study is that the screening method used to identify TA is a useful approach to finding more efficacious Btk inhibitors. (+info)There are several types of mastocytosis, including:
1. Cutaneous mastocytosis: This type affects the skin and can cause redness, itching, and hives.
2. Systemic mastocytosis: This type affects multiple organs and can cause a wide range of symptoms, such as abdominal pain, diarrhea, and difficulty breathing.
3. Aggressive mastocytosis: This is a rare and severe form of the disease that can cause rapid growth of mast cells and can lead to organ failure and death.
4. Mast cell sarcoma: This is a rare type of cancer that affects mast cells.
The symptoms of mastocytosis vary depending on the type and severity of the disorder, but they can include:
* Skin symptoms such as hives, itching, and flushing
* Abdominal pain
* Diarrhea
* Difficulty breathing
* Anaphylaxis (a severe allergic reaction)
The exact cause of mastocytosis is not known, but it is believed to be related to genetic mutations and environmental triggers. There is no cure for mastocytosis, but treatment options include medications to manage symptoms, such as antihistamines, corticosteroids, and chemotherapy in severe cases.
In conclusion, mastocytosis is a rare disorder characterized by an excessive increase in mast cells in certain tissues or organs, which can cause a wide range of symptoms. While there is no cure for the disease, treatment options are available to manage symptoms and improve quality of life.
Symptoms of anaphylaxis include:
1. Swelling of the face, lips, tongue, and throat
2. Difficulty breathing or swallowing
3. Abdominal cramps
4. Nausea and vomiting
5. Rapid heartbeat
6. Feeling of impending doom or loss of consciousness
Anaphylaxis is diagnosed based on a combination of symptoms, medical history, and physical examination. Treatment for anaphylaxis typically involves administering epinephrine (adrenaline) via an auto-injector, such as an EpiPen or Auvi-Q. Additional treatments may include antihistamines, corticosteroids, and oxygen therapy.
Prevention of anaphylaxis involves avoiding known allergens and being prepared to treat a reaction if it occurs. If you have a history of anaphylaxis, it is important to carry an EpiPen or other emergency medication with you at all times. Wearing a medical alert bracelet or necklace can also help to notify others of your allergy and the need for emergency treatment.
In severe cases, anaphylaxis can lead to unconsciousness, seizures, and even death. Prompt treatment is essential to prevent these complications and ensure a full recovery.
1. Cutaneous mastocytosis: This type of mastocytosis affects the skin and is characterized by the formation of raised, itchy bumps or hives on the skin.
2. Systemic mastocytosis: This type of mastocytosis affects multiple organs in the body and can cause a range of symptoms, including abdominal pain, diarrhea, fatigue, and difficulty breathing.
3. Aggressive systemic mastocytosis (ASM): This is a rare and severe form of systemic mastocytosis that can cause rapid progression of symptoms and can be life-threatening if left untreated.
4. Mast cell leukemia: This is a rare and aggressive form of mastocytosis that can progress to mast cell leukemia, a type of cancer.
The exact cause of mastocytosis is not known, but it is thought to be related to genetic mutations and environmental triggers such as allergens, infections, and stress. Diagnosis is based on a combination of clinical symptoms, physical examination findings, and laboratory tests, including a biopsy of affected tissue. Treatment options for mastocytosis depend on the severity of the disorder and can include medications to reduce inflammation and prevent allergic reactions, as well as surgery or chemotherapy in more severe cases.
What is Systemic Mastocytosis?
Systemic mastocytosis (SM) is a type of mastocytosis that affects multiple organs in the body. It is characterized by an excessive accumulation of mast cells in one or more organs, such as the skin, gastrointestinal tract, liver, spleen, and bone marrow. This accumulation can cause a range of symptoms, including abdominal pain, diarrhea, fatigue, weight loss, and anemia.
The symptoms of SM can vary in severity and may be similar to those of other conditions, making diagnosis challenging. Treatment options for SM depend on the severity of the disorder and can include medications to reduce inflammation and prevent allergic reactions, as well as surgery or chemotherapy in more severe cases.
What Causes Systemic Mastocytosis?
The exact cause of systemic mastocytosis is not known, but it is thought to be related to genetic mutations and environmental triggers such as allergens, infections, and stress. Some people may have an inherited predisposition to developing SM, while others may acquire the condition later in life due to exposure to environmental triggers.
Risk Factors for Systemic Mastocytosis
While anyone can develop systemic mastocytosis, there are certain risk factors that may increase the likelihood of developing the disorder. These include:
Genetics: People with a family history of mastocytosis or other allergic conditions may be at increased risk for SM.
Age: SM is more common in children and adolescents, but it can occur at any age.
Gender: Women are more likely to develop SM than men.
Allergies: People with allergies, especially those who experience severe allergic reactions, may be at increased risk for SM.
Autoimmune disorders: People with autoimmune disorders such as rheumatoid arthritis or lupus may be more likely to develop SM.
Exposure to environmental triggers such as insect stings, certain medications, or infections can also increase the risk of developing SM.
Diagnosis and Treatment of Systemic Mastocytosis
The diagnosis of systemic mastocytosis typically involves a combination of physical examination, medical history, and laboratory tests such as blood tests and biopsies to assess mast cell numbers and activity. Imaging studies such as X-rays or CT scans may also be used to assess the extent of organ involvement.
Treatment options for SM depend on the severity of symptoms, the organs involved, and the patient's overall health status. Treatment may involve one or a combination of the following:
Medications: Antihistamines, corticosteroids, and other medications that suppress mast cell activity may be used to control symptoms such as hives, itching, and swelling.
Monitoring and follow-up: Regular monitoring of the patient's condition and response to treatment is important to adjust therapy as needed.
Surgery: In some cases, surgical removal of affected tissue or organs may be necessary to control symptoms.
Supportive care: Patients with severe SM may require supportive care such as intravenous fluids, oxygen therapy, or feeding tubes to manage complications related to organ dysfunction.
Prognosis and Quality of Life
The prognosis for systemic mastocytosis varies depending on the severity of symptoms, the organs involved, and the patient's overall health status. In general, patients with mild forms of SM may have a good quality of life, while those with more severe forms of the disease may experience significant limitations in their daily activities.
Living with systemic mastocytosis can be challenging due to the unpredictable nature of symptoms and the potential for severe reactions. Patients with SM may experience anxiety, depression, and decreased quality of life as a result of their condition. However, with proper management and support, many patients with SM are able to lead active and fulfilling lives.
In conclusion, systemic mastocytosis is a rare and complex disorder that affects the body's mast cells and can cause a wide range of symptoms. While there is no cure for SM, early diagnosis and appropriate treatment can help manage symptoms and improve quality of life.
Note: This definition is an abstract from the online medical encyclopedia MedScape, which is available to healthcare professionals only. Please consult a qualified healthcare professional for further information and appropriate treatment.
Mast cell sarcoma is most commonly seen in the skin, but it can also arise in other parts of the body such as the spleen, liver, or gastrointestinal tract. The tumors are usually large, irregularly shaped masses that can be firm or soft to the touch. They may ulcerate and bleed easily, leading to swelling and discomfort.
The symptoms of mast cell sarcoma can vary depending on the location and size of the tumor. They may include:
* A lump or mass that may be painless or tender to the touch
* Swelling in the affected area
* Abdominal pain
* Diarrhea or constipation
* Fatigue
* Fevers
* Night sweats
Mast cell sarcoma is rare and accounts for only about 1-2% of all skin tumors. It is more common in dogs than cats and tends to affect older animals. The exact cause of mast cell sarcoma is not known, but genetic factors and environmental triggers may play a role.
Treatment options for mast cell sarcoma depend on the location and stage of the tumor. Surgery is often the first line of treatment to remove the tumor and any affected tissue. Additional therapies such as radiation, chemotherapy, or immunotherapy may be recommended based on the severity of the disease and the patient's overall health.
Prognosis for mast cell sarcoma varies depending on several factors, including the size and location of the tumor, the effectiveness of treatment, and the patient's overall health. In general, the prognosis is guarded and early detection and treatment are important to improve outcomes. With prompt and appropriate therapy, some patients with mast cell sarcoma can achieve long-term remission or even cure. However, in advanced cases or those that are resistant to treatment, the prognosis may be poorer.
There are several types of hypersensitivity reactions, including:
1. Type I hypersensitivity: This is also known as immediate hypersensitivity and occurs within minutes to hours after exposure to the allergen. It is characterized by the release of histamine and other chemical mediators from immune cells, leading to symptoms such as hives, itching, swelling, and difficulty breathing. Examples of Type I hypersensitivity reactions include allergies to pollen, dust mites, or certain foods.
2. Type II hypersensitivity: This is also known as cytotoxic hypersensitivity and occurs within days to weeks after exposure to the allergen. It is characterized by the immune system producing antibodies against specific proteins on the surface of cells, leading to their destruction. Examples of Type II hypersensitivity reactions include blood transfusion reactions and serum sickness.
3. Type III hypersensitivity: This is also known as immune complex hypersensitivity and occurs when antigens bind to immune complexes, leading to the formation of deposits in tissues. Examples of Type III hypersensitivity reactions include rheumatoid arthritis and systemic lupus erythematosus.
4. Type IV hypersensitivity: This is also known as delayed-type hypersensitivity and occurs within weeks to months after exposure to the allergen. It is characterized by the activation of T cells, leading to inflammation and tissue damage. Examples of Type IV hypersensitivity reactions include contact dermatitis and toxic epidermal necrolysis.
The diagnosis of hypersensitivity often involves a combination of medical history, physical examination, laboratory tests, and elimination diets or challenges. Treatment depends on the specific type of hypersensitivity reaction and may include avoidance of the allergen, medications such as antihistamines or corticosteroids, and immunomodulatory therapy.
There are two main types of mastocytoma: cutaneous mastocytoma, which affects the skin, and systemic mastocytosis, which can affect multiple organs throughout the body. Cutaneous mastocytoma typically appears as a firm, raised bump or nodule on the skin, and may be accompanied by itching or other symptoms. Systemic mastocytosis is more serious and can cause a wide range of symptoms, including abdominal pain, diarrhea, fatigue, and anemia.
The exact cause of mastocytoma is not known, but it is believed to be linked to genetic mutations and environmental factors such as exposure to toxins or allergens. Diagnosis is typically made through a combination of physical examination, biopsy, and laboratory tests. Treatment options for mastocytoma include surgery, chemotherapy, and medications to reduce histamine levels.
Prognosis for mastocytoma varies depending on the type and severity of the disease, but in general, the prognosis is good for most patients with this condition. With proper treatment, many patients can achieve long-term remission or even be cured. However, in some cases, mastocytoma can progress to more aggressive forms of cancer, such as mast cell leukemia, which can be difficult to treat and has a poorer prognosis.
Urticaria Pigmentosa typically presents in infancy or early childhood and can progress to more severe symptoms over time. In addition to the skin and eye changes, individuals with this condition may also experience joint pain, fatigue, and respiratory problems. There is currently no cure for Urticaria Pigmentosa, but various treatments are available to manage its symptoms and prevent complications.
The diagnosis of Urticaria Pigmentosa is based on a combination of clinical evaluation, family history, and genetic testing. Treatment options may include medications such as antihistamines, corticosteroids, and immunosuppressants, as well as phototherapy and laser therapy to manage skin lesions. In severe cases, bone marrow transplantation may be considered.
Prognosis for individuals with Urticaria Pigmentosa varies depending on the severity of the condition and the presence of any additional health problems. While some people with mild forms of the condition may experience few or no complications, others may develop more severe symptoms and require ongoing medical care throughout their lives. Regular monitoring and management by a healthcare team is essential to ensure the best possible outcome for individuals with Urticaria Pigmentosa.
The term "basophilic" refers to the staining properties of these abnormal cells, which have a distinctive appearance under a microscope. The disease is often referred to as "acute" because it progresses rapidly and can be fatal within weeks or months if left untreated.
There are two main subtypes of basophilic leukemia: acute and chronic. Acute basophilic leukemia is the more aggressive and common form of the disease, accounting for approximately 75% of all cases. It typically affects adults in their 40s and 50s and is characterized by a high white blood cell count, anemia, and splenomegaly (enlargement of the spleen).
Chronic basophilic leukemia, on the other hand, is a rarer form of the disease that progresses more slowly and typically affects adults in their 60s and 70s. It is characterized by a lower white blood cell count, splenomegaly, and an increased risk of developing myelodysplastic syndrome (a precancerous condition).
The exact cause of basophilic leukemia is not known, but it is believed to be linked to genetic mutations and exposure to certain chemicals or radiation. Treatment typically involves chemotherapy and/or bone marrow transplantation, and the prognosis varies depending on the subtype and overall health of the patient.
The symptoms of trichinellosis can vary depending on the severity of the infection and the number of parasites consumed. Mild cases may not exhibit any symptoms at all, while more severe cases can cause a range of symptoms including:
* Abdominal pain
* Diarrhea
* Fever
* Headache
* Muscle pain
* Skin rash
* Swelling of the face and eyelids
In severe cases, trichinellosis can lead to complications such as inflammation of the heart, brain, and liver, and can be fatal if left untreated.
Trichinellosis is diagnosed through a combination of physical examination, medical history, and laboratory tests such as blood tests or biopsies. Treatment typically involves antiparasitic drugs to kill the parasite, and supportive care to manage symptoms.
Prevention of trichinellosis primarily involves proper food handling and cooking practices, such as cooking meat to an internal temperature of at least 165°F (74°C) to kill any Trichinella parasites that may be present. Avoiding the consumption of raw or undercooked meat, particularly from wild game animals, can also help prevent the infection.
There are several key features of inflammation:
1. Increased blood flow: Blood vessels in the affected area dilate, allowing more blood to flow into the tissue and bringing with it immune cells, nutrients, and other signaling molecules.
2. Leukocyte migration: White blood cells, such as neutrophils and monocytes, migrate towards the site of inflammation in response to chemical signals.
3. Release of mediators: Inflammatory mediators, such as cytokines and chemokines, are released by immune cells and other cells in the affected tissue. These molecules help to coordinate the immune response and attract more immune cells to the site of inflammation.
4. Activation of immune cells: Immune cells, such as macrophages and T cells, become activated and start to phagocytose (engulf) pathogens or damaged tissue.
5. Increased heat production: Inflammation can cause an increase in metabolic activity in the affected tissue, leading to increased heat production.
6. Redness and swelling: Increased blood flow and leakiness of blood vessels can cause redness and swelling in the affected area.
7. Pain: Inflammation can cause pain through the activation of nociceptors (pain-sensing neurons) and the release of pro-inflammatory mediators.
Inflammation can be acute or chronic. Acute inflammation is a short-term response to injury or infection, which helps to resolve the issue quickly. Chronic inflammation is a long-term response that can cause ongoing damage and diseases such as arthritis, asthma, and cancer.
There are several types of inflammation, including:
1. Acute inflammation: A short-term response to injury or infection.
2. Chronic inflammation: A long-term response that can cause ongoing damage and diseases.
3. Autoimmune inflammation: An inappropriate immune response against the body's own tissues.
4. Allergic inflammation: An immune response to a harmless substance, such as pollen or dust mites.
5. Parasitic inflammation: An immune response to parasites, such as worms or fungi.
6. Bacterial inflammation: An immune response to bacteria.
7. Viral inflammation: An immune response to viruses.
8. Fungal inflammation: An immune response to fungi.
There are several ways to reduce inflammation, including:
1. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs).
2. Lifestyle changes, such as a healthy diet, regular exercise, stress management, and getting enough sleep.
3. Alternative therapies, such as acupuncture, herbal supplements, and mind-body practices.
4. Addressing underlying conditions, such as hormonal imbalances, gut health issues, and chronic infections.
5. Using anti-inflammatory compounds found in certain foods, such as omega-3 fatty acids, turmeric, and ginger.
It's important to note that chronic inflammation can lead to a range of health problems, including:
1. Arthritis
2. Diabetes
3. Heart disease
4. Cancer
5. Alzheimer's disease
6. Parkinson's disease
7. Autoimmune disorders, such as lupus and rheumatoid arthritis.
Therefore, it's important to manage inflammation effectively to prevent these complications and improve overall health and well-being.
Mast cell
Mast cell sarcoma
Mast cell stabilizer
Mast cell leukemia
Mast cell activation syndrome
CFU-Mast
Diathesis-stress model
Immune system
Omalizumab
Hoplobatrachus tigerinus
Collagen receptor
Boxer (dog)
Allergy
Dog health
Antileukotriene
MCD peptide
Schmidt sting pain index
Skin cancer in cats and dogs
Jack Russell Terrier
Giemsa stain
Medication
Beta-2 adrenergic receptor
Fast-scan cyclic voltammetry
Inflammation
Phagocyte
Margaret Hurlstone Hardy Fallding
Basophil
FCER1
Light mast
Histamine N-methyltransferase
Sparassis
O2 (UK)
Fibroblast-like synoviocyte
CD34
Myelopoiesis
Bepotastine
Stephen Holgate (physician)
Peranema
N-Arachidonoyl dopamine
Dafna Bar-Sagi
Histamine H3 receptor
2022 in the United States
Japan Academy Prize (academics)
Jathi Ratnalu
Cholesterol 24-hydroxylase
Lunar Lander (spacecraft)
Lyme disease
GL Mk. III radar
Allergic inflammation
Interleukin 25
Lichen planus
Sutton Hoo
Interleukin 3
Convent of São Pedro de Alcântara (São Roque do Pico)
FCER1A
Profilin 1
Louth, Lincolnshire
INPP5D
Pattern recognition receptor
List of active Indonesian Navy ships
IgE and mast cells: The endogenous adjuvant
Bürgerwelle News: East residents object to cell mast construction
Information for "Mast cell tumor" - wikidoc
Expression of the cellular prion protein by mast cells in the human carotid body. | ALZFORUM
mast cell activation Archives - Hack your gut
Association of Mast Cells with Warthin's Tumor in Fine Needle Aspirates of the Salivary Gland | Acta Cytologica | Karger...
Singulair: Singulair mast cells, mast cell, dust mites, asthma sufferers, imm...
Follicular, parafollicular and mast cells in mouse thyroid gland after antithyroid drug application | Université de Liège
The expression of vascular endothelial growth factor in mast cells promotes the neovascularisation of human pterygia | British...
Orbit/Mast, the CLASP orthologue of Drosophila, is required for asymmetric stem cell and cystocyte divisions and development of...
IgE-activated mast cells enhance TLR4-mediated antigen-specific CD4+ T cell responses - List Labs
Blast those masts! Conquering mast cell tumors in your veterinary patients
The Chymase, Mouse Mast Cell Protease 4, Constitutes the Major Chymotrypsin-like Activity in Peritoneum and Ear Tissue. A Role...
IL-3 dependent mast cells undergo apoptosis on removal of IL-3: Prevention of apoptosis by c-kit ligand | CiNii Research
Enzymes Mast Cell 360
Leukemia
Jackie's story | Mast Cell Action
Mast Cell Activation
Relationship between mast cells and T cells in infammation
Powerhouse - Level 2 - Mast Cell Advanced Diagnostics
Mast cell disease at The Medical Dictionary
Biology Pictures: Structure and Function of Mast Cells
CSI Laboratories Mast Cell (reflex panel) - CSI Laboratories
Mast cells trigger epithelial barrier dysfunction, bacterial translocation and postoperative ileus in a mouse model. |...
The human factor in allergy research - USC News & Events | University of South Carolina
Mast Cell Tumors #2 [MP3] - Dog Cancer Blog Store
Don't do this Archives - Hell's Bells and Mast Cells
Molecular Mechanisms of Mast Cell Activation by Cholesterol-Dependent Cytolysins
Omega-3 fatty acid epoxides produced by PAF-AH2 in mast cells regulate pulmonary vascular remodeling<...
Histamine6
- Mast cell activation syndrome(MCAS) treatment normally centers around blocking histamine. (hackyourgut.com)
- You've likely heard of histamine as the release of histamine from mast cells causes allergic symptoms. (hackyourgut.com)
- If a dog with a mast cell tumor is sick when it comes in, blame histamine, heparin and other vasoactive amines. (dvm360.com)
- Histamine is a signaling molecule, sending messages between cells. (medlineplus.gov)
- Antihistamines block cells from seeing histamine and can treat common allergies. (medlineplus.gov)
- Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. (bvsalud.org)
Tumor4
- Mast cell tumors are the most common cutaneous tumor in dogs, accounting for 16% to 21% of skin tumors.1 Risk factors include age (there's a higher incidence in older dogs) and breed (boxers, Boston terriers, Labradors, beagles and schnauzers are at higher risk). (dvm360.com)
- The way a mast cell tumor looks to your naked eye in the exam room correlates well with how it looks on a slide. (dvm360.com)
- Here's a fun fact: Darier's sign refers to the wheal and flare in surrounding tissues after manipulation of a mast cell tumor and is caused by mast cell degranulation. (dvm360.com)
- It can also be especially difficult to predict which grade 1 and grade 2 mast cell tumors will result in death due to the mast cell tumor. (dvm360.com)
Eosinophils3
- Thus in the case of asthma, it is known that excessive numbers of eosinophils appear in the airways and these cells create inflammation. (medications.com)
- Merck says in the literature that montelukast binds with the cysLT1 receptor in order to prevent the mast cell from signalling the eosinophils to arrive in excessive numbers that cause inflammation. (medications.com)
- Chronic lesions also display increased mast cells, eosinophils, and IgE-bearing Langerhans cells. (medscape.com)
Mediators4
- Mast cells are potent mediators of allergy and asthma, yet their role in regulating adaptive immunity remains ambiguous. (listlabs.com)
- This study provides important new evidence to support the role of mast cells as mediators of the antigen-specific adaptive immune response. (listlabs.com)
- Upon contact with allergen, sensitized mast cells release highly active proinflammatory mediators. (the-medical-dictionary.com)
- The mast cells are cellular types that execute a series of functions through the release of chemical mediators when duly stimulated, interacting with some cells of the most different origins. (bvsalud.org)
MCAS2
- In typical mast cell activation syndrome (MCAS) fashion, the last day of the AKC National Agility Championship was a bit of shock. (hellsbellsandmastcells.com)
- I try not to set expectations, because it's impossible to anticipate all the variables that could trigger a MCAS reaction, but still, even after five years of diagnosis, my mast cells surprise me. (hellsbellsandmastcells.com)
Mastocytosis2
- In addition, we discuss the evaluation and treatment of mast cell activation ( syndromes ), allergy and anaphylaxis in mast cell disorders, and the clinical and biologic heterogeneity of the more indolent forms of mastocytosis . (bvsalud.org)
- Because mast cell disorders are relatively rare, AIM hopes to achieve a coordination of scientific efforts not only in the Americas but also in Europe by collaborating with the well-established European Competence Network on Mastocytosis . (bvsalud.org)
Lymphocytes1
- Le pourcentage de CD44 dans les lymphocytes T périphériques était significativement plus élevé chez les patients que chez les témoins, comme détecté par la cytométrie en flux. (who.int)
Basophils2
- Eventually mast cells and basophils pick up the IgE's and become sensitized. (medlineplus.gov)
- Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. (bvsalud.org)
Degranulation1
- RESULTS: Immediately after vibration, the tails were hyperalgesic and had disrupted myelinated axons, fragmented nerve endings, and mast-cell degranulation. (cdc.gov)
Disease3
- The overarching goal of this meeting was to establish a Pan-American organization of physicians and scientists with multidisciplinary expertise in mast cell disease . (bvsalud.org)
- To serve this unmet need, AIM envisions a network where basic, translational, and clinical researchers could establish collaborations with both academia and biopharma to support the development of new diagnostic methods , enhanced understanding of the biology of mast cells in human health and disease , and the testing of novel therapies . (bvsalud.org)
- Pemphigus vulgaris (PV) is a life-threate- disorders and to shed a light on the role of ning blistering skin disease in which pa- mast cells in autoimmune diseases [ 7 ]. (who.int)
Tissue4
- The Chymase, Mouse Mast Cell Protease 4, Constitutes the Major Chymotrypsin-like Activity in Peritoneum and Ear Tissue. (rupress.org)
- It's not a skin cell, but it's found throughout skin tissue. (sc.edu)
- It's not a lung cell, but it's found throughout lung tissue. (sc.edu)
- Working with human tissue presents challenges, including less regular access to cells, which are typically derived from tummy tucks and biopsies by the NIH-affiliated outfit that supplies him, but Gomez prefers to be closer to the species of real interest. (sc.edu)
Endogenous1
- however, little is known about the mast cell contribution to the induction of endogenous, antigen-specific CD4 + T cells. (listlabs.com)
Biology1
- In these AIM proceedings, we highlight selected topics relevant to mast cell biology and provide updates regarding the recently described hereditary alpha-tryptasemia. (bvsalud.org)
Dependent2
- The localisation of CLIP-190 to such microtubules and to the fusome is dependent upon Orbit/Mast to which it is complexed. (caltech.edu)
- This enhanced activation was dependent on global TLR4 stimulation but appeared to be less dependent on mast cell expressed TLR4. (listlabs.com)
Tissues3
- Mast cell tumors are most common in dermal and subcutaneous tissues. (dvm360.com)
- A body's immune system places mast cells, which are a form of white blood cell, in stationary positions in tissues. (sc.edu)
- Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. (bvsalud.org)
Immune cells4
- When the mast cell knows that pathogens are present and nitric oxide is NOT produced, then it signals other immune cells to be sent to the site of the infection. (medications.com)
- I believe that montelukast probably creates a source of nitric oxide that prevents the mast cell from signalling for other immune cells to arrive at the source of infection. (medications.com)
- When the immune system discovers an invader, immune cells called B-cells make IgE antibodies. (medlineplus.gov)
- The IgE's are like "WANTED" signs that spread throughout the body, telling other immune cells about specific invaders to look for. (medlineplus.gov)
Invaders2
- Mast cells are cells of the immune system that help protect the body against foreign invaders. (hackyourgut.com)
- In other words, they're white blood cells that are permanently positioned outside of the bloodstream, and they're responsible for a number of functions, including fighting off invaders. (sc.edu)
Stem cell f1
- Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR. (bvsalud.org)
Biochemical1
- The mast cell is capable of many different types of biochemical functions that are designed to signal other cells or other chemical responses. (medications.com)
Responses1
- Bombesin-like peptides and mast cell responses: Relevance to bronchopulmonary dysplasia? (the-medical-dictionary.com)
Diseases3
- Mast cell diseases comprise a heterogeneous spectrum of diseases involving the mast cells. (the-medical-dictionary.com)
- Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. (bvsalud.org)
- The American Initiative in Mast Cell Diseases (AIM) held its inaugural investigator conference at Stanford University School of Medicine in May 2019. (bvsalud.org)
Epithelial1
- Epithelial cells. (cdc.gov)
Antigen-specific1
- Here we examined the effects of specific mast cell activation in vivo on the initiation of an antigen-specific CD4 + T cell response. (listlabs.com)
Cellular1
- Expression of the cellular prion protein by mast cells in the human carotid body. (alzforum.org)
Mitotic3
- In wild-type cysts, the Orbit/Mast protein not only associates with the mitotic spindle and its poles, but also with the central spindle (spindle remnant), ring canal and fusome, suggesting it participates in interactions between these structures. (caltech.edu)
- The Orbit/Mast protein thus appears to facilitate multiple interactions of the fusome with mitotic spindles and ring canals. (caltech.edu)
- Mitotic index (MI) is an indirect measure of cell proliferation based on the number of mitotic figures present. (dvm360.com)
Diagnostics1
- However, these diagnostics are of questionable value in staging since mast cells are also present in healthy animals. (dvm360.com)
Interactions2
- It is known despite the interactions between mast cells and cells T exist, however not yet are very clear. (bvsalud.org)
- CD117 by immunohistochemical methods sion molecules, involved in cell-cell and in order to clarify the role of the infiltrating cell matrix interactions and thought to take inflammatory cells in the pathomechanisms part in cell motility [ 2,3 ]. (who.int)
Allergy1
- In conjunction with T-helper cells, allergy in the chemical industry. (cdc.gov)
Eventually1
- In orbit mutants, the stem cells and their associated fusomes are eventually lost as Orbit/Mast protein is depleted. (caltech.edu)
Role1
- An initiating role should be ascribed to the mast cells because their reaction occurs at the earliest time and is in average the most expressed. (ac.be)
Protein2
- We show that the Orbit/Mast microtubule-associated protein is required at several stages in the formation of such polarised 16-cell cysts. (caltech.edu)
- Finally the Orbit/Mast protein is required during mid-oogenesis for the organisation of the polarised microtubule network inside the 16-cell cyst that ensures oocyte differentiation. (caltech.edu)
Ratio3
- The absolute volumes, expressed as a ratio of the experimental to the control values, shows a similar increase for all three cell lines between the 4th and 32nd day. (ac.be)
- After this time the volume ratio for mast cells shows a further sharp increase, for follicular cells a moderate increase, and for parafollicular cells a decrease. (ac.be)
- Closely packed cells with indistinct cytoplasmic boundaries, nuclear-cytoplasmic ratio lower than with the anaplastic type, infrequent mitoses, and more granules than with the anaplastic type. (dvm360.com)
Relationship1
- The objective of this work was to carry through a literary revision of the related current aspects of this possible relationship between mast cells and T cells in inflammatory process. (bvsalud.org)
Bound1
- bound to the surface of mast cells. (cdc.gov)
Adaptive1
- It is becoming clear however that this pair has important immunomodulatory effects on innate and adaptive cells of the immune system. (nih.gov)
Typically1
- Well-differentiated mast cell tumors are typically single, 1 to 4 cm in diameter, slow-growing, rubbery, non-ulcerated and alopecic. (dvm360.com)
Molecules1
- Suppression of IgE-mediated mast cell activation can be exerted by molecules targeting IgE, FcɛRI or signaling kinases including Syk, or by IgG antibodies acting via inhibitory Fcγ receptors. (nih.gov)
Skin1
- Mast cells are found in the skin, airways, intestines etc. (medications.com)
Receptor1
- I arrived at that conclusion from studying the chemical structure of montelukast, the chemical structure of the gene cysLT1 receptor, and the chemical structure of the cell wall of fungus which would be what the mast cell uses to determine "what to do in order to kill the fungus. (medications.com)
Human2
- CXCL10/CXCR3 Axis Mediates Human Lung Mast Cell Migration to Asthmatic Airway Smooth Muscle, The Mast cell microlocalization within the airway smooth muscle bundle is an important determinant of the asthmatic phenotype. (the-medical-dictionary.com)
- But I really wanted to learn the human mast cell system, and so over seven years ago I transitioned, and now in the lab we work exclusively with human mast cells. (sc.edu)
Patients1
- En outre, il y avait une aug- mentation significative de la forme soluble du c-kit dans le sérum des patients atteints de pemphigus vulgaire actif par rapport aux témoins. (who.int)
Inflammation1
- Each mast cell contains a grab bag of inflammation-causing chemicals that can be released if the immune system directs it to do so. (sc.edu)
Functions1
- In 2015 we reviewed the evidence for the adjuvant functions of mast cells. (nih.gov)
Substances1
- Blood vessels become leakier, so that white blood cells and other protective substances can sneak through and fight the invader. (medlineplus.gov)
Large1
- Undifferentiated mast cell tumors are large, rapidly growing, ulcerated and irritated. (dvm360.com)
Body1
- That cell is the mast cell, which is an immune cell that permeates just about all of the organs of the body. (sc.edu)
Common1
- Up to 60% of mast cell tumors show up on the trunk and 25% on the limbs, with the head and neck the least common sites. (dvm360.com)